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Trichosporon funginemia is a rare and fatal fungal infection which occurs in 
patients with prolonged neutropenia associated with hematologic 
malignancies.  A 21-year-old male developed Trichosporon funginemia 
during remission induction therapy for acute myeloid leukemia (AML).  
Although two courses of induction therapy failed to induce a remission of 
AML, combination therapy with voriconazole and liposomal amphotericin B 
(L-AmB) followed by monocyte colony-stimulating factor (M-CSF) 
ameliorated theTrichosporon funginemia and enabled the patient to receive 
reduced-intensity bone marrow transplantation (BMT) from his HLA-A 
one-locus mismatched mother.  The patient achieved a durable remission 
after BMT without exacerbation of Trichosporon funginemia.  The 
combination therapy with voriconazole and L-AmB may therefore be useful 
in controlling Trichosporon funginemia associated with prolonged 
neutropenia after remission induction therapy for AML.   
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Trichosporon funginemia is a rare and fatal fungal infection which occurs in 
patients with prolonged neutropenia associated with hematologic 
malignancies.  The funginemia presents with persistent fever and often 
involves the skin, kidneys, and other organs.  Trichosporon funginemia is 
becoming an increasing problem because it occurs as a breakthrough 
infection in patients being treated with antifungal agents due to its 
resistance to most antifungal agents. The treatment outcome is usually poor, 
with a mortality rate of 80% (1).  We recently experienced a patient with 
acute myelogenous leukemia (AML) complicated by Trichosporon funginemia 
who was successfully treated with combination therapy consisting of 
voriconazole, liposomal amphotericin B (L-AmB) and monocyte 
colony-stimulating factor (M-CSF). 
 
Case Report 
A 21-year-old male was diagnosed to have AML M0 expressing CD7 and 
CD33 with complicated chromosomal abnormalities on May 7, 2009.  He 
received induction chemotherapy consisting of idarubicin and cytosine 
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arabinoside. Ciprofloxacin, 600 mg/day, was used for antibacterial 
prophylaxis.  Cefepime and micafungin were administered to treat febrile 
neutropenia that occurred on day10, and the high fever eventually resolved.  
However, a high fever (over 40°C) recurred on day18, and cefepime was 
therefore changed to meropenem in combination with vancomycin.    
Trichosporon species were cultured from 5 consecutively drawn peripheral 
blood cultures on days 18-20 in the absence of a central venous line.  T. 
asahii was identified by a culture-based method using API ID32C clinical 
yeast identification system (Biomerieux SA, Marcy-L'Etoile, France).  The 
in vitro antifungal susceptibilities of the isolates from patients to antifungal 
drugs were determined using the Clinical and Laboratory Standards 
Institute (NCCLS) M-27 microdilution method.  The minimum inhibitory 
concentrations of each antifungal agent against the T. asahii isolate at 24h 
and 48h were as follows; amphotericin B, 0.5 and >16; 5-fluorocytosine, 4 and 
32; fluconazole, 16 and 16; miconazole, 0.5 and 1; itraconazole, 1 and 2; 
micafungin, >16 and >16; voriconazole, 0.25 and 0.25.  Treatment was 
changed to voriconazole on day 19 and supplemented by L-AmB (AmBisome, 
Dainippon Sumitomo Pharma Co., Osaka, Japan, 2.5 mg/kg) on day 
5 
 
20 because the outcome of treatment for Trichosporon funginemia with 
voriconazole alone in the absence of hematologic recovery is reported to be 
extremely poor (2-4).  Vancomycin was discontinued on day 20.  The blood 
cultures became negative for Trichosporon 2 days after the start of 
voriconazole and L-AmB, but a high fever surpassing 40°C persisted over the 
next 7 days.  In addition to high fever over 40°C for a week, the patient 
complained of pains in the right testis and gingivae in association with high 
fever.  He was diagnosed to have pericoronitis and acute epididymitis.  
Liver function abnormalities such as AST 29 IU/L, ALT 76 IU/L, and total 
bilirubin 2.2 mg/dL as well as an increase in the C-reactive protein level (9.1 
mg/dL) appeared a week after the onset of high fever.  All these data 
gradually normalized after the voriconazole/L-AmB treatment.  The 
leukocyte count on day 20 was 0.26 x 109/l with 100% leukemic cells.  Bone 
marrow aspiration performed on day 20 revealed that more than 90% of the 
cells were leukemic cells.   
Since there was a fear that granulocyte colony-stimulating factor 
(G-CSF) might stimulate leukemic cell proliferation, M-CSF (mirimostim, 
Kyowa Hakko Kirin Co., 8 x 106 U/day) was administered on day 24.  On 
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day 27, the leukocyte count was 0.32 x 109/l with a neutrophil count of 0.20 x 
109/l (63%) and a leukemic cell count of 0.03 x 109/l (8%) and the patient’s 
high fever gradually resolved.  However, bone marrow aspiration performed 
on day 32 again showed 80% of the cells to be leukemic cells.  Re-induction 
chemotherapy consisting of daunorubicin and cytosine arabinoside failed to 
induce a remission.  The blood cultures remained negative for Trichosporon, 
although voriconazole alone had been continued during re-induction therapy.   
The patient’s white blood cell count was 1.75 x 109/l, with 85% 
leukemia cells on day 24 after the start of re-induction therapy.  Allogeneic 
stem cell transplantation was considered to be the only curative measure for 
this patient due to the primary induction failure at this time point.  His 
mother was selected as a donor because she was HLA-A one locus 
mismatched with the patient.  Gemtuzumab ozogamicin (GO 6 mg/m2) was 
started on day 24 from the re-induction therapy (day-21 of BMT) and 3 
mg/m2 was added on day-14 for reducing the the leukemic burden.  
Following a conditioning regimen consisting of fludarabine (25 mg/m2, day-7 
to day-3), melphalan (40 mg/m2, day-3 to day-2), rabbit anti-thymocyte 
globulin (Thymoglobuline, 0.5 mg/kg day-3, 1.25 mg/kg day-2 to day-1 ) and 4 
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Gy of TBI (day-2), 1.52 x 108 bone marrow cells/kg per patient weight from 
his mother were infused.  Cyclosporine A and short term MTX were used for 
GVHD prophylaxis.  Engraftment was documented on day 15, and complete 
donor type chimerism was confirmed on day 21.  Grade Ia GVHD (skin 1, 
gut 0, liver 0) proven by a skin biopsy developed on day 56.  Intravenous 
voriconazole was continued until day 28, and Trichosporon remained 
negative from the start of GO until his discharge on day 99 after BMT.   
The patient died of AML 4 months after undergoing a third stem cell 
transplantation from an HLA-haplo-identical brother due to a relapse of 
leukemia on day 140.  Trichosporon funginemia never recurred after the 
first BMT.  No autopsy was performed.   
 
Discussion 
The incidence of invasive Trichosporon infection in patients with acute 
leukemia was reported to be 0.4% in a previous multicenter study performed 
in Italy (5).   Disseminated Trichosporon infections in immunocompromised 
or neutropenic patients are usually fatal, despite intensive treatments with 
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various antifungal agents (6, 7).  Trichosporon species are resistant to most 
antifungal agents, including fluconazle, itraconazole, and flucytosine (8-10).  
Trichosporon shows varying sensitivities to amphotericin B from one species 
to another.  The minimum concentration of amphotericin B at 24h that 
inhibited the growth of T. asahi isolated from our patient was 0.5g/mL.  
The in vitro sensitivity of the isolated Trichosporon to amphotericin B may 
explain the treatment success observed in our patient.  New triazoles such 
as voriconazole, posaconazole, and ravuconazole show excellent fungicidal 
activities in vitro and may be promising agents for the treatment of 
trichosporonosis (11).   
Fournier et al. reported a case of disseminated trichosporonosis which 
was refractory to combination therapy with FLCZ and AmB despite the fact 
that hematologic recovery was achieved, but the infection was later resolved 
with voriconazole (12).   Matsue et al. recently experienced 4 cases of 
disseminated trichosporonosis that developed under micafungin therapy (4).  
One of their patients who showed hematologic recovery was successfully 
treated with voriconazole, but the remaining 3 patients without hematologic 
recovery did not respond to fluconazole or voriconazole.  Some pediatric 
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reports have suggested the clinical efficacy of voriconazole in the treatment 
of trichosporonosis as monotherapy (2) or as a combination therapy with 
amphotericin B (3), but none of the reported patients who failed to achieve a 
hematologic recovery were cured from infection.  Therefore, although 
voriconazole shows a potent antifungal activity against Trichosporon species 
in vitro, it cannot effectively control the Trichosporon funginemia that 
develops in patients with persistent neutropenia, such as those with AML 
refractory to chemotherapy.    
Our current patient developed Trichosporon funginemia on day 20 after 
remission induction therapy for AML at the time when the induction failure 
became evident.  Since a very poor outcome of voriconazole treatment was 
predicted from the reappearance of leukemic cells and the absence of 
neutrophils, L-AmB was co-administered.  Despite the fact that severe 
neutropenia of less than 0.1 x 109/l persisted over a week, the patient’s 
Trichosporon funginemia was well-controlled by the combination therapy, 
and was eventually remitted in association with hematologic recovery that 
was accelerated by M-CSF.  Even though several factors other than 
antifungal therapy may have contributed to the treatment success, this is to 
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our knowledge the first case of Trichosporon funginemia that was 
ameliorated by combination therapy in the absence of neutrophilic recovery.   
M-CSF is a cytokine known to exert anti-fungal activity through the 
activation of monocytes (13).  Although Trichosporon became undetectable 
in the patient’s blood after the start of voriconazole and L-AmB, the high 
fever persisted in our patient.  G-CSF was not used due to the persistence of 
leukemic cells in the peripheral blood.  However, his high fever readily 
resolved in association with a gradual increase in the neutrophil count that 
occurred 3 days after the start of M-CSF.  Therefore, the antifungal activity 
of M-CSF may have contributed to the improvement of the patient’s 
funginemia.  
Allogeneic stem cell transplantation is a curative treatment option for 
patients with refractory acute myeloid leukemia (AML), but it is generally 
difficult to achieve success with this option when the patients are 
complicated by severe infections such as Trichosporon funginemia.  Our 
patient achieved a complete remission (CR) after preconditioning with GO 
and a reduced-intensity regimen followed by BMT.  The patient’s clinical 
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course indicates that even when a patient with chemotherapy-resistant AML 
is complicated by Trichosporon funginemia, reduced-intensity BMT can 
induce a durable remission of AML with the help of voriconazole and L-AmB 
treatment.  The combination therapy for Trichosporon funginemia therefore 
warrants further clinical investigation.   
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